Abstract | BACKGROUND/AIM: MATERIALS AND METHODS: Cell proliferation assays were performed on MDA-MB-231, Hs578T, MCF7 and HCC1806 cell lines at varying time points with Z285 and 4-OHT alone and in combination. Furthermore, ROS activity was measured to determine the changes in oxidative stress caused by both drugs. RESULTS: The results showed dose- and time-dependent decreases in proliferation for all cell lines when treated with Z285, 4-OHT and their combination. Combinatorial analysis performed at 72 h using Synergyfinder® showed additive effects in MCF7, HCC1806 and Hs578T and an antagonistic response in MDA-MB-231. Z285 caused a significant increase in ROS production in three cell lines after 8 h, but HCC1806 showed no change in effect. CONCLUSION: These promising results suggest the independent ability of each compound as a stand-alone chemotherapeutic agent, or in combinatorial therapy for the treatment of TNBC.
|
Authors | Anastasia G J Robinson, Yasmine M Kanaan, Robert L Copeland |
Journal | Anticancer research
(Anticancer Res)
Vol. 40
Issue 12
Pg. 6623-6635
(Dec 2020)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 33288557
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone
- Naphthoquinones
- Reactive Oxygen Species
- Tamoxifen
- afimoxifene
|
Topics |
- Apoptosis
(drug effects)
- Cell Line, Tumor
- Cell Survival
(drug effects)
- Drug Synergism
- Female
- Humans
- Inhibitory Concentration 50
- Naphthoquinones
(pharmacology)
- Reactive Oxygen Species
(metabolism)
- Tamoxifen
(analogs & derivatives, pharmacology)
- Triple Negative Breast Neoplasms
(pathology)
|